Please use this identifier to cite or link to this item: http://dspace.dtu.ac.in:8080/jspui/handle/repository/19814
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBHARDWAJ, SHANU-
dc.date.accessioned2023-06-09T06:04:27Z-
dc.date.available2023-06-09T06:04:27Z-
dc.date.issued2023-05-
dc.identifier.urihttp://dspace.dtu.ac.in:8080/jspui/handle/repository/19814-
dc.description.abstractAlzheimer’s Disease is progressive disorder whose pathophysiology and therapeutic status still stands unclear. As of now, all the therapies are confined to symptomatic relief, disease modifying therapies are therefore the need of the hour. Modulation in Wnt cascade has already been linked to varied disorders which include AD and type 2 diabetes mellitus too. The interlink between insulin signaling pathway and Wnt cascade has been well acknowledged through a number of preclinical and clinical studies. This in silico-based study is focused upon investigating the link between curative effects of FDA approved anti- diabetic drug and Wnt signaling cascade. We prepared a library consisting of 143 FDA approved antidiabetic medicines with an aim of repurposing them as GSK 3 beta inhibitor, which is present in increased amounts in AD brain. Pharmacophore modelling was performed for these drugs and the lead hits were then subjected to ligand- protein based molecular docking followed by molecular dynamics simulation. ZINC04803471 emerged as a clear winner that can inhibit GSK 3 beta, which leads to beta catenin degeneration and thereby downregulates the canonical Wnt signaling cascade in the AD brain. Although this is just a tip of an iceberg, further in vitro investigation is necessary to validate the effectiveness of the compound.en_US
dc.language.isoenen_US
dc.relation.ispartofseriesTD-6398;-
dc.subjectDRUG REPURPOSING APPROACHen_US
dc.subjectPHARMACOPHORE MODELINGen_US
dc.subjectMOLECULAR DOCKINGen_US
dc.subjectALZHEIMER’S DISEASEen_US
dc.subjectGSK-3β MODULATIONen_US
dc.titleA DRUG REPURPOSING APPROACH THROUGH PHARMACOPHORE MODELING AND MOLECULAR DOCKING TO MANAGE ALZHEIMER’S DISEASE VIA GSK-3β MODULATIONen_US
dc.typeThesisen_US
Appears in Collections:M Sc

Files in This Item:
File Description SizeFormat 
Shanu Bhardwaj M.Sc..pdf2.5 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.